NatWest Group’s Insys Therapeutics, Inc. INSY Stock Holding History

NatWest Group’s Portfolio INSY Stock Details INSY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-19,316	Closed	-$550K	–	374
2015 Q3	$550K	Sell	19,316 -7,856	-29%	-$289K	0.01%	267
2015 Q2	$976K	Sell	27,172 -11,460	-30%	-$357K	0.01%	194
2015 Q1	$1.12M	Sell	38,632 -3,230	-8%	-$85.4K	0.01%	210
2014 Q4	$882	Buy	+41,862	New	+$828K	0.01%	230

Other funds holding INSY

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FHAM

Folger Hill Asset Management New York $16.5M AUM 19.96% 1-Year Est. Return

GAM

Gotham Asset Management New York $32.7B AUM 27.65% 1-Year Est. Return

NatWest Group's INSY Position: Q4 2015 in Review

NatWest Group sold out of Insys Therapeutics, Inc. (INSY) in Q4 2015, closing a stake of 19,316 shares — an estimated $550K sold.

NatWest Group first reported a position in INSY in Q4 2014 and held it in 4 quarters. The position peaked at $1.12M in Q1 2015. 154 funds tracked by Wall St. Rank hold INSY as of Q4 2015.

NatWest Group reported no remaining Insys Therapeutics, Inc. position as of Q4 2015 after selling out during the quarter.
NatWest Group sold 19,316 Insys Therapeutics, Inc. shares in Q4 2015, an estimated $550K.
NatWest Group first reported a position in Insys Therapeutics, Inc. in Q4 2014 and held it in 4 quarters.
NatWest Group's Insys Therapeutics, Inc. position peaked at $1.12M in Q1 2015.
154 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q4 2015.

Based on NatWest Group's 13F filing for Q4 2015, filed 16 Feb 2016.